Global Vascular Closing Device Market Size By Type (Disposable, Reusable), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Vascular Closing Device Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.05 billion by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. Vascular closing devices (VCDs) are extensively used to achieve hemostasis after catheterization procedures, particularly following angiography and interventional procedures. The increasing number of cardiovascular procedures, rising adoption of minimally invasive surgeries, and growing geriatric population with cardiovascular ailments are key drivers of market expansion. Technological advancements and the shift towards rapid ambulation and early discharge protocols further support market growth.

Drivers:

1. Rising Number of Cardiovascular Procedures:

The increasing global prevalence of cardiovascular diseases has led to a surge in diagnostic and interventional procedures, boosting the demand for vascular closing devices for faster hemostasis and patient recovery.

2. Shift Toward Minimally Invasive Procedures:

Minimally invasive endovascular surgeries are replacing traditional open procedures, increasing the use of catheterization, which in turn fuels the need for effective vascular closure techniques.

3. Focus on Early Discharge and Patient Comfort:

Hospitals are emphasizing early patient ambulation to reduce stay durations and operational costs. VCDs enable quicker hemostasis and reduce post-procedure complications, supporting this trend.

Restraints:

1. Risk of Complications:

Despite their benefits, VCDs carry a risk of complications such as infection, hematoma, or vessel occlusion, which may hinder market acceptance among certain patient populations or in low-resource settings.

2. High Cost of Devices:

The relatively high cost of vascular closing devices compared to manual compression, especially in price-sensitive regions, could limit their widespread adoption.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Asia-Pacific and Latin America are investing in healthcare infrastructure and adopting advanced medical technologies, offering significant growth opportunities for VCD manufacturers.

2. Development of Bioabsorbable and User-Friendly Devices:

Innovation in materials and ease-of-use—such as bioabsorbable plugs and fully automated deployment systems—are poised to drive adoption in outpatient and ambulatory care settings.

Market by System Type Insights:

Among system types, Extravascular Devices accounted for the largest market share in 2023. These systems, which operate without entering the vessel lumen, are increasingly preferred due to their lower complication rates and ease of use. However, Active Approximators, offering faster closure and high precision, are expected to witness the fastest growth during the forecast period, driven by rising procedural volumes and advancements in technology.

Market by End-use Insights:

In 2023, Hospitals dominated the market by end-use, accounting for over 60% of revenue. Their high procedural volume, presence of trained professionals, and focus on reducing hospital stays drive the demand for VCDs. Meanwhile, the Ambulatory Surgical Centers (ASCs) segment is poised for rapid growth, fueled by the rising trend of outpatient interventional procedures and the need for cost-effective post-operative care.

Market by Regional Insights:

North America led the global vascular closing device market in 2023, attributed to high healthcare expenditure, advanced cardiovascular care infrastructure, and strong penetration of VCDs. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by a growing elderly population, expanding healthcare systems, and increased awareness of minimally invasive treatments.

Competitive Scenario:

Key players in the global vascular closing device market include Abbott Laboratories, Terumo Corporation, Cardinal Health, Cardiva Medical, Inc., Essential Medical, Inc., Vascular Solutions, Inc., Morris Innovative, Inc., Medtronic plc, and St. Jude Medical (now part of Abbott). Companies are emphasizing product innovation, strategic acquisitions, and geographic expansion to gain a competitive edge.

Scope of Work – Global Vascular Closing Device Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.05 billion

CAGR (2023–2031) 7.9%

Key Segments by System Type Extravascular Devices, Active Approximators

Key Segments by End-use Hospitals, Ambulatory Surgical Centers

Leading Region North America

Key Players Abbott Laboratories, Terumo Corporation, Medtronic, Cardinal Health, Cardiva Medical

Growth Drivers Rising cardiovascular procedures, minimally invasive surgery adoption, early ambulation trends

Opportunities Emerging market expansion, bioabsorbable & automated device development

Key Market Developments:

2023: Abbott received FDA approval for its next-generation VCD designed for femoral access site closure, enhancing deployment precision and patient safety.

2024: Terumo launched a new extravascular closure sy